Dear readers,
Many women in perimenopause or those diagnosed with PCOS (Polycystic Ovary Syndrome) struggle with weight gain that feels resistant to diet, exercise, or even traditional hormone therapy. While these issues are often attributed to shifts in estrogen, progesterone, or testosterone, there’s growing evidence that metabolic health — particularly insulin sensitivity — plays a deeper role.
This is where GLP-1 medications, even in microdoses, may offer an innovative solution.
What Are GLP-1 Agonists?
GLP-1 (glucagon-like peptide-1) agonists are a class of medications originally developed to treat type 2 diabetes. Medications like Ozempic®, Wegovy®, Mounjaro®, and Zepbound® (known generically as semaglutide or tirzepatide) work by improving insulin sensitivity, controlling blood sugar, and reducing appetite.
At full doses, these medications are known for their powerful effects on weight loss. But recent interest has emerged in using lower, microdosed versions — especially for women whose weight issues are rooted in hormonal and metabolic imbalances.
Why Hormonal Symptoms May Be Metabolic in Nature
Hormones like estrogen, progesterone, and testosterone play critical roles in energy, mood, and body composition. But behind these well-known hormones is another player: insulin.
Insulin is a hormone that regulates blood sugar and overall metabolic function. When insulin resistance is present — which is common in both PCOS and perimenopause — it can lead to:
- Weight gain (especially around the midsection)
- Inflammation
- Brain fog
- Fatigue
- Hormonal imbalances
In women with PCOS, insulin resistance contributes to irregular periods, elevated androgens (male hormones), and fertility challenges. In perimenopause, fluctuating estrogen and progesterone levels may be worsened by impaired insulin regulation, making weight loss even harder.
How Microdosing GLP-1s Can Help
Unlike standard doses used for diabetes or rapid weight loss, microdoses of GLP-1 medications are significantly lower — but still effective for certain women. The goal isn’t extreme weight loss, but rather a gentle reset of the body’s metabolic and hormonal balance.
Potential benefits of microdosing GLP-1s may include:
- Improved insulin sensitivity
- Gradual, sustainable weight loss
- Regulated menstrual cycles in women with PCOS
- Decrease in excess androgens
- Better balance of estrogen and progesterone
- Reduced brain fog, inflammation, and fatigue
- Enhanced response to lifestyle efforts (diet, exercise, sleep)
Why Choose Microdosing Over Full Doses?
While full-dose GLP-1 therapies may lead to rapid weight loss, they can also come with side effects such as nausea, fatigue, or GI issues. Microdosing minimizes these risks while still supporting core metabolic functions.
This approach may be ideal for women who:
- Aren’t looking for dramatic weight loss, but want to overcome stubborn plateaus
- Are already following a healthy lifestyle but not seeing results
- Prefer a lower-risk intervention to support hormones and metabolism
The Bottom Line
Microdosing GLP-1 medications represents a promising new frontier in supporting hormonal and metabolic health, particularly for women navigating perimenopause or PCOS. By addressing insulin resistance at its root, this strategy helps the body respond better to healthy habits — and allows hormonal therapies to work more effectively.
While research is still evolving, many women are finding relief through this more personalized, lower-dose approach.
To your health,
Dr. Alex Gajer
